• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Wang Stephen Hui

    10/10/25 4:34:58 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Wang Stephen Hui

    (Last) (First) (Middle)
    C/O IMAGENEBIO, INC.
    12526 HIGH BLUFF DRIVE, SUITE 345

    (Street)
    SAN DIEGO CA 92130

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/25/2025
    3. Issuer Name and Ticker or Trading Symbol
    ImageneBio, Inc. [ IMA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney. This Form 3 is being filed late due to delays in obtaining the reporting person's EDGAR codes.
    No securities are beneficially owned.
    /s/ Erin Butler, Attorney-in-Fact 10/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMA

    DatePrice TargetRatingAnalyst
    10/24/2025$30.00Outperform
    Leerink Partners
    More analyst ratings

    $IMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " "Company")), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander 37th Annual Healthcare ConferenceFireside Chat: Thursday, December 4, 10:00am ESTNew York, NY To access the live webcasts or subsequent archived recordings of the presentation and f

    11/6/25 8:30:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory ("I&I") diseases, granted equity awards to Dr. Kristin Yarema, ImageneBio's recently appointed Chief Executive Officer, on July 28, 2025 that were recommended by the Compensation Committee of its Board of Directors (the "Board") and approved by the Board. The grant included (i) inducement stock options to purchase 436,080 shares of common stock; and (ii) inducement restricted stock units ("RSUs") for 153,505 shares of common stock (together, the "Inducement Awards"). The Inducement

    8/1/25 4:15:00 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on ImageneBio with a new price target

    Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00

    10/24/25 9:00:36 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    SEC Filings

    View All

    SEC Form 8-K filed by ImageneBio Inc.

    8-K - ImageneBio, Inc. (0001835579) (Filer)

    11/5/25 4:05:32 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by ImageneBio Inc.

    424B3 - ImageneBio, Inc. (0001835579) (Filer)

    11/5/25 4:07:46 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by ImageneBio Inc.

    424B3 - ImageneBio, Inc. (0001835579) (Filer)

    10/30/25 4:35:37 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Slattery Joseph P

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    11/7/25 5:15:40 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wang Stephen Hui was granted 250,721 shares (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    10/10/25 4:37:16 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Wang Stephen Hui

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    10/10/25 4:34:58 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care